PAA

0.00%

19.5¢ pharmaust limited

The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-689

First 689 Last

Share
Profile

Follow
Captain Goodvybes

3,248 Posts.

471

02/03/24

21:53

Post #: 72714939
Share

Originally posted by Captain Goodvybes: ↑

There are several ways that options can be considered in the context of a T/O and ASX/ASIC have regulations governing such.

Firstly, the rights that attach to an option cannot simply be nullified by the target company nor the acquiring company without due consideration (ie. Money) unless there was some bizarre clause in the option terms that was somehow legally sound.
The most common method is for the options to be cancelled, yet paid out based on the intrinsic price (ie. T/O price of heads less exercise price) This is because the market for those options ceases to exist, so the opinion of the market cannot be called apon to establish risk/value over time. There is also the presumption that any T/O offer accepted by shareholders would be at the maximum attainable value of the company (and options) anyway. So whether an option has 1 year or 2 years to run is moot.

In the case of ResApp there was a premium paid above the intrinsic value- most likely done at the discretion of the buyer. Why? Well all options accounted for only 1% of the T/O price, so it was probably a good tactic to spend a fraction of a % on paying premium above intrinsic. Even the 43c opptions which never had a hope in hell of converting and had zero intrinsic value still got some value attributed to them- just a way to grease the wheels? (some of those options may also have been held by directors??)

In most cases a company goes into and out of TH throughout a takeover period, so there is also the old fashioned way of converting or selling that holders can use.

There are other ways the options can be realised, a Google search will reveal all.

I haven't read the letter re. Bpay yet from what posters say, it just looks like a window of convenience to induce holders to convert within a time that suits the company.

I doubt it has anything to do with any T/O talks. Remember we only got topline results. So any suitor would still be sifting through the fine print before jumping into a transaction.
If anything, the company is looking at suring up funds so that it can do the trials without a full T/O.
It would be completely insane to accept a ph1 value T/O now when all we need to do is raise 30 or 40m to get to ph3 value.

Expand

Ps. DYOR re above

PAA Price at posting: 30.0¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

VMS

Venture to sniff out high-grade REE targets at Jupiter project, WA

WGX

Westgold sets its sights on top five producer status through merger with Karora

VMT

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

DVP

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

BOE

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

MGU

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

GRX

GreenX picks up prospective copper project in Germany

NXG

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Is oil undervalued?

There are more pages in this discussion • 736 more messages in this thread...

First 689 Last

Add PAA (ASX) to my watchlist

(20min delay)
Last 19.5¢		Change 0.000(0.00%)		Mkt cap ! $94.81M

Open	High	Low	Value	Volume
19.5¢	19.5¢	19.0¢	$212.6K	1.118M

Buyers (Bids)

No.	Vol.	Price($)
2	7234	19.0¢

Sellers (Offers)

Price($)	Vol.	No.
19.5¢	260069	3

View Market Depth

No.	Vol.	Price($)
2	7234	0.190
10	211175	0.185
13	301185	0.180
3	284030	0.175
2	174892	0.170

Price($)	Vol.	No.
0.195	260069	3
0.200	348393	9
0.205	222000	3
0.210	238902	5
0.215	255948	3

Last trade - 16.10pm 02/08/2024 (20 minute delay)

PAA (ASX) Chart

The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-689

Venture to sniff out high-grade REE targets at Jupiter project, WA

Westgold sets its sights on top five producer status through merger with Karora

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

GreenX picks up prospective copper project in Germany

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Is oil undervalued?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-689

Top Stories

Venture to sniff out high-grade REE targets at Jupiter project, WA

Westgold sets its sights on top five producer status through merger with Karora

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

GreenX picks up prospective copper project in Germany

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Is oil undervalued?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News